Qualigen Therapeutics Files 8-K
Ticker: AIXC · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1460702
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Qualigen Therapeutics filed an 8-K on Sept 5th, updating corporate info. Check it out.
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on September 5, 2024, reporting other events and financial statements. The filing details the company's corporate structure and operational information, including its principal executive offices located at 5857 Owens Avenue, Suite 300, Carlsbad, California.
Why It Matters
This filing provides an update on Qualigen Therapeutics' corporate and financial status, which is important for investors to understand the company's current operational standing.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new financial or operational risks.
Key Numbers
- 001-37428 — Commission File Number (Identifies the company's SEC filing history)
- 26-3474527 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- September 5, 2024 (date) — Date of earliest event reported
- 5857 Owens Avenue, Suite 300, Carlsbad, California (location) — Address of principal executive offices
- RITTER PHARMACEUTICALS INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of September 5, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Qualigen Therapeutics, Inc.
Where are Qualigen Therapeutics, Inc.'s principal executive offices located?
Qualigen Therapeutics, Inc.'s principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What was the former name of Qualigen Therapeutics, Inc.?
The former name of Qualigen Therapeutics, Inc. was RITTER PHARMACEUTICALS INC.
On what date was the company's name changed from Ritter Pharmaceuticals Inc.?
The date of the name change from Ritter Pharmaceuticals Inc. was April 2, 2009.
Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-09-05 09:25:32
Key Financial Figures
- $3.46 million — nouncing the pricing of approximately a $3.46 million public offering. A copy of the press re
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 10KB
- 0001493152-24-035102.txt ( ) — 224KB
- qlgn-20240905.xsd (EX-101.SCH) — 3KB
- qlgn-20240905_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240905_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: September 5, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer